Drugs Made In America Acquisition Corp. (DMAAU) Stock Price, Financials & Summary

Price chart

Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3

Key dataNov 3, 2026

Open$11.15

From 52W high−1.50%

Volume203.00

Market cap$373.72M

P/E (TTM)56.8x

P/S (TTM)—

Div yield—

Key dataNov 3, 2026

Open

$11.15

From 52W high

−1.50%

Volume

203.00

Market cap

$373.72M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−142.3x

P/E (TTM)

56.8x

RSI (14)

63.6

MomentumView details →

1D Return

+1.27%

YTD Return

+6.09%

SummaryUpdated Jun 1, 2026

Drugs Made In America Acquisition Corp. (NASDAQ:DMAAU) is a special purpose acquisition company (SPAC) founded on May 23, 2024, and headquartered in Fort Lauderdale, Florida. The company went public on January 27, 2025, as a blank check company designed to identify and merge with or acquire businesses in the pharmaceutical and healthcare sectors. As a newly formed entity, DMAAU operates as an investment vehicle seeking to complete a business combination with one or more target companies, with a particular focus on businesses involved in domestic pharmaceutical manufacturing and related healthcare services.

Ask drillr about Drugs Made In America Acquisition Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

56.8x

EV/EBITDA

−142.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

4.42%

ROA (TTM)

4.15%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−99.85%

FCF YoY

+46.96%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+439.29%

EBITDA YoY

—

MomentumView details →

1D Return

+1.27%

YTD Return

+6.09%

1Y Return

+5.29%

RSI (14)

63.6

vs 50D SMA

+1.91%

vs 200D SMA

+3.83%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

0.02x

Quick Ratio

0.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

6.09M

Op. CF (TTM)

−323129.00

Latest newsMore news →

Drugs Made In America Acquisition Corp. entered into an Amended and Restated Definitive Merger Agreement with Power Analytics Global Corp, fixing a closing valuation of US$2.85 billion for the merger.51d ago

Similar companies

Bleichroeder Acquisition Corp. IIBBCQ Aldabra 4 Liquidity Opportunity Vehicle Inc.ALOV Yorkville International Capital Corp.YICC Zero2IPO Holdings Inc.01945.HK Crane Harbor Acquisition Corp. II UnitsCRANU Karbon Capital Partners Corp. UnitsKBONU Find similar companies →

Latest newsMore news →